Patents by Inventor Herman Rutner

Herman Rutner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10161934
    Abstract: Biosensor components (chips) are described based on direct biocoating processes that result in the tenacious and stable, noncovalent (believed to be chemisorptive) binding of anchor substances such as avidin(s) other proteins having specific binding partners or oligo- or poly-nucleotides onto any piezo-electrically active crystal surface. The resulting platform technology can be developed for a variety of biosensors with specific applications in biological assays. The table mono layers of the anchor substances forms reactive layers, ready to bind a capture reagent such as a biot-inylated antibody for capture and detection of analytes in biologic fluid samples.
    Type: Grant
    Filed: August 27, 2012
    Date of Patent: December 25, 2018
    Assignee: Aviana Molecular Technologies, LLC
    Inventors: Lisa Laury-Kleintop, Herman Rutner
  • Publication number: 20150111765
    Abstract: Biosensor components (chips) are described based on direct biocoating processes that result in the tenacious and stable, noncovalent (believed to be chemisorptive) binding of anchor substances such as avidin(s) other proteins having specific binding partners or oligo- or poly-nucleotides onto any piezo-electrically active crystal surface. The resulting platform technology can be developed for a variety of biosensors with specific applications in biological assays. The table mono layers of the anchor substances forms reactive layers, ready to bind a capture reagent such as a biot-inylated antibody for capture and detection of analytes in biologic fluid samples.
    Type: Application
    Filed: August 27, 2012
    Publication date: April 23, 2015
    Applicant: AVIANA MOLECULAR TECHNOLOGIES, LLC.
    Inventors: Lisa Laury-Kleintop, Herman Rutner
  • Patent number: 8337755
    Abstract: The present invention provides a protocol and apparatus for enriching circulating tumor cells and other rare cells from blood, including debris and other components, from samples with high precision and at high throughput rates. This invention discloses an improved processing system from previously described semi-automated sample processing. The system further reduces operator intervention and hands-on time from prior systems. While this system has general utility in processing diverse materials, the system is configured for sample processing of biological specimens to provide an enriched fraction suitable for detection, enumeration and identification of target cells by appropriate analytical methodologies.
    Type: Grant
    Filed: March 13, 2006
    Date of Patent: December 25, 2012
    Assignee: Veridex, LLC
    Inventors: Teresa Bendele, Thomas Harbart, Dave Howard, Michael Kagan, Douglas Keene, Dave Lapeus, Jared Mayes, Douglas Paynter, Jerry Prohaska, Herman Rutner
  • Patent number: 8329422
    Abstract: The methods and reagents described in this invention are used to analyze circulating tumor cells, clusters, fragments, and debris. Analysis is performed with a number of platforms, including flow cytometry and the CELLSPOTTER® fluorescent microscopy imaging system. Analyzing damaged cells has shown to be important. However, there are two sources of damage: in vivo and in vitro. Damage in vivo occurs by apoptosis, necrosis, or immune response. Damage in vitro occurs during sample acquisition, handling, transport, processing, or analysis. It is therefore desirable to confine, reduce, eliminate, or at least qualify in vitro damage to prevent it from interfering in analysis. Described herein are methods to diagnose, monitor, and screen disease based on circulating rare cells, including malignancy as determined by CTC, clusters, fragments, and debris. Also provided are kits for assaying biological specimens using these methods.
    Type: Grant
    Filed: November 2, 2010
    Date of Patent: December 11, 2012
    Assignee: Veridex LLC
    Inventors: Galla Chandra Rao, Christopher Larson, Madeline Repollet, Herman Rutner, Leon W. M. M. Terstappen, Shawn Mark O'Hara, Steven Gross
  • Publication number: 20110136262
    Abstract: An integrated multiplexed acoustic wave biosensor chip system with enhanced sensitivity has been developed. The biosensor system incorporates one or more microfluidic channels, coated with target-specific binding films enabling rapid and early detection of viral, bacterial or parasitic targets such as Dengue virus and sexually transmitted diseases in specimens from potentially infected patients. The biosensors are used in portable analytical systems that are suitable for real-time point of care (POC) clinical diagnosis in cost sensitive and/or resource limited settings. The highly sensitive biosensors utilize thinned single crystal piezoelectric substrates that propagate layer guided shear horizontal acoustic plate mode (LG-SH-APM) waves in sensing regions bearing immobilized binders that provide simultaneous and direct detection of mass changes due to multiple bound target pathogens or molecules.
    Type: Application
    Filed: May 28, 2010
    Publication date: June 9, 2011
    Inventors: Vanaja Vijaya Ragavan, Avijit Roy, Herman Rutner
  • Publication number: 20110104718
    Abstract: The methods and reagents described in this invention are used to analyze circulating tumor cells, clusters, fragments, and debris. Analysis is performed with a number of platforms, including flow cytometry and the CellSpotter® fluorescent microscopy imaging system. Analyzing damaged cells has shown to be important. However, there are two sources of damage: in vivo and in vitro. Damage in vivo occurs by apoptosis, necrosis, or immune response. Damage in vitro occurs during sample acquisition, handling, transport, processing, or analysis. It is therefore desirable to confine, reduce, eliminate, or at least qualify in vitro damage to prevent it from interfering in analysis. Described herein are methods to diagnose, monitor, and screen disease based on circulating rare cells, including malignancy as determined by CTC, clusters, fragments, and debris. Also provided are kits for assaying biological specimens using these methods.
    Type: Application
    Filed: November 2, 2010
    Publication date: May 5, 2011
    Applicant: VERIDEX, LLC
    Inventors: Galla Chandra Rao, Christopher Larson, Madeline Repollet, Herman Rutner, Leon W.M.M. Terstappen, Shawn Mark O'Hara, Steven Gross
  • Patent number: 7863012
    Abstract: The methods and reagents described in this invention are used to analyze circulating tumor cells, clusters, fragments, and debris. Analysis is performed with a number of platforms, including flow cytometry and the CellSpotter® fluorescent microscopy imaging system. Analyzing damaged cells has shown to be important. However, there are two sources of damage: in vivo and in vitro. Damage in vivo occurs by apoptosis, necrosis, or immune response. Damage in vitro occurs during sample acquisition, handling, transport, processing, or analysis. It is therefore desirable to confine, reduce, eliminate, or at least qualify in vitro damage to prevent it from interfering in analysis. Described herein are methods to diagnose, monitor, and screen disease based on circulating rare cells, including malignancy as determined by CTC, clusters, fragments, and debris. Also provided are kits for assaying biological specimens using these methods.
    Type: Grant
    Filed: February 17, 2004
    Date of Patent: January 4, 2011
    Assignee: Veridex, LLC
    Inventors: Galla Chandra Rao, Christopher Larson, Madeline Repollet, Herman Rutner, Leon W. M. M. Terstappen, Shawn Mark O'Hara, Steven Gross
  • Patent number: 7282350
    Abstract: Methods and kits for used as an internal or external control in rare cell analysis are disclosed. A plurality of fluorescently distinct sets of cells is used to define a range to assess the isolation of rare target cells from a sample. Thus, a known number of cells, expressing the surface and intracellular antigens present in the targeted rare cells, are stabilized and modified in such a way that they can be discriminated from the targeted rare cells. In addition, these cells are separated into at least two sets based upon the number. These sets are detectably distinct from each other and provide an upper and lower indication of the detection ability of the rare cell assay.
    Type: Grant
    Filed: November 12, 2003
    Date of Patent: October 16, 2007
    Assignee: Immunivest Corporation
    Inventors: Galla Chandra Rao, Herman Rutner
  • Publication number: 20070212698
    Abstract: The present invention provides a protocol and apparatus for enriching circulating tumor cells and other rare cells from blood, including debris and other components, from samples with high precision and at high throughput rates. This invention discloses an improved processing system from previously described semi-automated sample processing. The system further reduces operator intervention and hands-on time from prior systems. While this system has general utility in processing diverse materials, the system is configured for sample processing of biological specimens to provide an enriched fraction suitable for detection, enumeration and identification of target cells by appropriate analytical methodologies.
    Type: Application
    Filed: March 13, 2006
    Publication date: September 13, 2007
    Inventors: Teresa Bendele, Thomas Harbart, Dave Howard, Michael Kagan, Douglas Keene, Dave Lapeus, Jared Mayes, Douglas Paynter, Jerry Prohaska, Herman Rutner
  • Publication number: 20060194192
    Abstract: Compositions and methods for stabilizing rare cells in blood specimens, preserving the quality of blood specimens, and also serving as cell fixatives are disclosed which minimize losses of target cells (for example, circulating tumor cells) and formation of debris and aggregates from target cells, non-target cells and plasma components, thereby allowing more accurate analysis and classification of circulating tumor cells (CTC) and, ultimately, of tumor burdens in cancer patients. Stabilization of specimens is particularly desirable in protocols requiring rare cell enrichment from blood specimens drawn from cancer patients. Exposure of such specimens to potentially stressful conditions encountered, for example, in normal processing, mixing, shaking, delays due to transporting the blood, has been observed to not only diminish the number of CTC but also to generate debris and aggregates in the blood specimens that were found to interfere with accurate enumeration of target cells, if present.
    Type: Application
    Filed: April 28, 2006
    Publication date: August 31, 2006
    Inventors: Galla Rao, Melissa Herman, Herman Rutner, Leon Terstappen
  • Publication number: 20050181463
    Abstract: The methods and reagents described in this invention are used to analyze circulating tumor cells, clusters, fragments, and debris. Analysis is performed with a number of platforms, including flow cytometry and the CellSpotter® fluorescent microscopy imaging system. Analyzing damaged cells has shown to be important. However, there are two sources of damage: in vivo and in vitro. Damage in vivo occurs by apoptosis, necrosis, or immune response. Damage in vitro occurs during sample acquisition, handling, transport, processing, or analysis. It is therefore desirable to confine, reduce, eliminate, or at least qualify in vitro damage to prevent it from interfering in analysis. Described herein are methods to diagnose, monitor, and screen disease based on circulating rare cells, including malignancy as determined by CTC, clusters, fragments, and debris. Also provided are kits for assaying biological specimens using these methods.
    Type: Application
    Filed: February 17, 2004
    Publication date: August 18, 2005
    Inventors: Galla Rao, Christopher Larson, Madeline Repollet, Herman Rutner, Leon Terstappen, Shawn O'Hara, Steven Gross
  • Publication number: 20050181353
    Abstract: Compositions and methods for stabilizing rare cells in blood specimens, preserving the quality of blood specimens, and also serving as cell fixatives are disclosed which minimize losses of target cells (for example, circulating tumor cells) and formation of debris and aggregates from target cells, non-target cells and plasma components, thereby allowing more accurate analysis and classification of circulating tumor cells (CTC) and, ultimately, of tumor burdens in cancer patients. Stabilization of specimens is particularly desirable in protocols requiring rare cell enrichment from blood specimens drawn from cancer patients. Exposure of such specimens to potentially stressful conditions encountered, for example, in normal processing, mixing, shaking, delays due to transporting the blood, has been observed to not only diminish the number of CTC but also to generate debris and aggregates in the blood specimens that were found to interfere with accurate enumeration of target cells, if present.
    Type: Application
    Filed: February 17, 2004
    Publication date: August 18, 2005
    Inventors: Galla Rao, Melissa Herman, Herman Rutner, Leon Terstappen
  • Publication number: 20040072269
    Abstract: Methods and kits for used as an internal or external control in rare cell analysis are disclosed. A plurality of fluorescently distinct sets of cells is used to define a range to assess the isolation of rare target cells from a sample. Thus, a known number of cells, expressing the surface and intracellular antigens present in the targeted rare cells, are stabilized and modified in such a way that they can be discriminated from the targeted rare cells. In addition, these cells are separated into at least two sets based upon the number. These sets are detectably distinct from each other and provide an upper and lower indication of the detection ability of the rare cell assay.
    Type: Application
    Filed: November 12, 2003
    Publication date: April 15, 2004
    Inventors: Galla Chandra Rao, Herman Rutner
  • Publication number: 20010018192
    Abstract: Stabilized control cells, methods for making the same and kits comprising the stabilized cells are disclosed. Also provided are improved methods for detecting rare cells in biological samples.
    Type: Application
    Filed: March 7, 2001
    Publication date: August 30, 2001
    Inventors: Leon W.M.M. Terstappen, Galla Chandra Rao, Herman Rutner, Paul A. Liberti
  • Patent number: 5646256
    Abstract: The present invention is directed to methods for using reagents to generate and stabilize thiols derived from thiol precursors in order to permit more effective reactions with thiol-reactive substances such as liposomes, proteins and antibodies. These methods provide greatly improved conjugates for utilization in various in vivo and in vitro applications.
    Type: Grant
    Filed: September 19, 1994
    Date of Patent: July 8, 1997
    Assignee: Becton, Dickinson and Company
    Inventors: William Shackelford, Josephine Readio, Samuel L. Moore, Herman Rutner
  • Patent number: 5366895
    Abstract: A method for rapidly lysing liposomes having transition temperatures in the range of 35.degree. to 65.degree. C. is provided. Such liposomes are treated with a surfactant including ##STR1## wherein x represents an average of 9 or 12. The method is applicable to fluorescence immunoassay procedures.
    Type: Grant
    Filed: March 5, 1990
    Date of Patent: November 22, 1994
    Assignee: Becton, Dickinson and Company
    Inventors: Herman Rutner, Abdul M. Butt, Josephine D. Readio, Lewis Pollack
  • Patent number: 5248590
    Abstract: A liposome reagent encapsulating a molecule to be targeted to a body site or used as an assay reporter has a ligand and a sulfonate-containing group on the liposome surface. Preferred ligands are antibodies or antibody fragments and preferred encapsulants are enzymes or dyes. In the most preferred reagents, the antibody and sulfonate-containing group are covalently bonded to the liposome surface through a connecting group which includes a succinimidyl group resulting from addition of the ligand or sulfonate-containing group to a maleimidyl group. The invention includes a kit of materials for performing an assay using the reagent of the invention as the tracer.
    Type: Grant
    Filed: July 22, 1991
    Date of Patent: September 28, 1993
    Assignee: Becton, Dickinson and Company
    Inventors: Herman Rutner, Josephine D. Readio, Leslie Oppenheimer
  • Patent number: 5164320
    Abstract: A method for rapidly lysing liposomes having transition temperatures in the range of 35.degree. C. to 65.degree. C. is provided. Such liposomes are treated with a surfactant including polyethyleneglycol mono-n-alkyl ethers such as C.sub.12 H.sub.25 O(CH.sub.2 CH.sub.2 O).sub.n H where n=9-10, a nine mole ethylene oxide adduct of a blend of n-dodecanol, n-tetradecanol and n-hexadecanol, or other appropriate polyethyleneglycol mono-n-alkyl ether capable of causing rapid lysis. The method is applicable to fluorescence immunoassay procedures.
    Type: Grant
    Filed: March 5, 1990
    Date of Patent: November 17, 1992
    Assignee: Becton, Dickinson and Company
    Inventors: Herman Rutner, Abdul M. Butt, Marie M. Sylvestre, Josephine D. Readio, Lewis Pollack
  • Patent number: 4310675
    Abstract: Monoradioiodinated derivatives of compounds employed in a radioassay prepared from precursors which are either active esters, amino acids, or amines, including a phenolic of imidazole substituent group in which one of the possible two sites on the group for radioiodination is substituted to permit production of a monoradioiodinated derivative. A preferred precursor is an active ester of 3-fluoro-5-radioiodotyrosine which can be coupled to a compound including an amino group to produce a monoradioiodinated derivative of the compound.
    Type: Grant
    Filed: May 24, 1979
    Date of Patent: January 12, 1982
    Assignee: Becton Dickinson & Company
    Inventors: Anandrao S. Akerkar, Herman Rutner
  • Patent number: 4276280
    Abstract: Derivatives of folic acid wherein the .alpha.-carboxyl group of the glutamyl moiety is substituted with a radical which is capable of being radioiodinated, such as, substituted and unsubstituted tyrosyl and histidyl. The radioiodinated derivatives can be employed as tracers for the assay of folates.
    Type: Grant
    Filed: September 29, 1976
    Date of Patent: June 30, 1981
    Assignee: Becton, Dickinson and Company
    Inventors: Anandrao S. Akerkar, Herman Rutner